

USSN 09/690,647

Group Art Unit: 1635

Remarks

Claims 1-28 are pending. Claim 12 has been amended. Support for the amendment can be found throughout the specification. No new matter has been added.

In response to the Restriction Requirement, Applicants hereby provisionally elect with traverse to prosecute the claims of Group I, i.e., claims 1 and 3-28, which are drawn to methods of using an ERK1/2 inhibitor, with traverse. The traversal is to the extent that no undue burden would be required to search all groups. The traversal is also to the extent that the restriction requirement should be a species election.

Applicants note that claim 12 is drawn to a method comprising administering two inhibitors. In view of the election of ERK1/2, claim 12 has been amended for purposes of clarity by specifying that the other inhibitor is an inhibitor of JNK. Applicants respectfully submit that claim 12 should not be restricted out, since the subject matter of the claim also pertains to ERK1/2.

Conclusion

If a telephone conversation with Applicant's Attorney would expedite prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 832-1000.

Respectfully submitted,
FOLEY, HOAG LLP



Isabelle M. Clauss, Ph.D.
Attorney for Applicants
Reg. No. 47,326

Patent Group
FOLEY, HOAG LLP
155 Seaport Boulevard
Boston, MA 02210
(617) 832-1000
Customer No: 2518

Date: September 25, 2002

USSN 09/690,647

Group Art Unit: 1635

Replacement claim 12 showing changes made

12. (Amended) The method of claim 1, further comprising administering to the subject an inhibitor of [the ERK/MAP kinase pathway] JNK.